Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZTS
stocks logo

ZTS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.37B
+2.48%
1.429
+2.06%
2.34B
+5.28%
1.573
+6.25%
2.59B
+5.1%
1.864
+5.93%
Estimates Revision
The market is revising Downward the revenue expectations for Zoetis Inc. (ZTS) for FY2025, with the revenue forecasts being adjusted by -0.6% over the past three months. During the same period, the stock price has changed by -19.04%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.28%
In Past 3 Month
Stock Price
Go Down
down Image
-19.04%
In Past 3 Month
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 181.71 USD with a low forecast of 152.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 181.71 USD with a low forecast of 152.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 121.250
sliders
Low
152.00
Averages
181.71
High
215.00
Current: 121.250
sliders
Low
152.00
Averages
181.71
High
215.00
Piper Sandler
David Westenberg
Overweight
downgrade
$215 -> $190
2025-11-10
New
Reason
Piper Sandler
David Westenberg
Price Target
$215 -> $190
2025-11-10
New
downgrade
Overweight
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Zoetis to $190 from $215 following quarterly results. The firm keeps an Overweight rating on the shares.
Morgan Stanley
Overweight
downgrade
$211 -> $175
2025-11-10
New
Reason
Morgan Stanley
Price Target
$211 -> $175
2025-11-10
New
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Zoetis to $175 from $211 and keeps an Overweight rating on the shares.
JPMorgan
Overweight
downgrade
$230 -> $200
2025-11-05
Reason
JPMorgan
Price Target
$230 -> $200
2025-11-05
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Zoetis to $200 from $230 and keeps an Overweight rating on the shares post the Q3 report. The firm reduced estimates to reflect slower growth in 2025 and 2026 but says this is already priced into the shares.
UBS
Neutral
downgrade
$158 -> $141
2025-11-05
Reason
UBS
Price Target
$158 -> $141
2025-11-05
downgrade
Neutral
Reason
UBS lowered the firm's price target on Zoetis to $141 from $158 and keeps a Neutral rating on the shares. Macro weakness is adding a new wrinkle to the firm's thesis, the analyst tells investors in a research note.
Stifel
Hold
downgrade
$155 -> $140
2025-11-04
Reason
Stifel
Price Target
$155 -> $140
2025-11-04
downgrade
Hold
Reason
Stifel lowered the firm's price target on Zoetis to $140 from $155 and keeps a Hold rating on the shares. Something seemingly had to give, the firm says. Stifel notes Zoetis revised 2025 revenue lower and its 2026/2027 estimates, which were already below Street, move lower. While Zoetis remains upbeat about 2026 growth prospects, the second half of 2025 volume likely exits at 0% growth. Looking forward, the anchor from Librela likely eases but share pressures in Dermatology, and to a lesser extent, Parasiticides, may get worse. The firm awaits its upcoming International and U.S. AH survey diligence to further assess share trends across key franchises.
UBS
Neutral
downgrade
$165 -> $158
2025-10-20
Reason
UBS
Price Target
$165 -> $158
2025-10-20
downgrade
Neutral
Reason
UBS lowered the firm's price target on Zoetis to $158 from $165 and keeps a Neutral rating on the shares. The firm is incrementally cautious on Zoetis into the print.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zoetis Inc (ZTS.N) is 18.14, compared to its 5-year average forward P/E of 32.34. For a more detailed relative valuation and DCF analysis to assess Zoetis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
32.34
Current PE
18.14
Overvalued PE
38.25
Undervalued PE
26.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average EV/EBITDA
22.54
Current EV/EBITDA
13.74
Overvalued EV/EBITDA
26.02
Undervalued EV/EBITDA
19.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
10.17
Current PS
120.12
Overvalued PS
20.02
Undervalued PS
0.32
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 228.26% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ZTS News & Events

Events Timeline

(ET)
2025-11-04
10:01:13
Zoetis Experiences a 13.1% Decline
select
2025-11-04
07:45:01
Zoetis reaffirms FY25 adjusted EPS guidance of $6.30-$6.40, in line with consensus of $6.35
select
2025-11-04
07:42:33
Zoetis announces Q3 adjusted earnings per share of $1.70, surpassing consensus estimate of $1.62
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-06Benzinga
JP Morgan Keeps Overweight Rating on Zoetis, Reduces Price Target to $200

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
4.5
11-05NASDAQ.COM
Stocks Close Significantly Down Amid Worries Over High Valuations

  • US Stock Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed lower, with the S&P 500 hitting a 1.5-week low, driven by concerns over high valuations, particularly in AI stocks like Palantir Technologies, which fell over 7% despite better-than-expected earnings.

  • Economic Outlook and Interest Rates: Wall Street banks warned of a potential 10% pullback in equity markets within the next 12 to 24 months, while the markets are pricing in a 69% chance of a rate cut at the upcoming FOMC meeting, amid ongoing concerns about the longest US government shutdown in history.

  • Corporate Earnings Trends: Q3 earnings season is strong, with 80% of S&P 500 companies beating forecasts, but profit growth is expected to slow to 7.2% year-over-year, the smallest increase in two years, indicating mixed signals in corporate performance.

  • Global Market Movements: Overseas markets also declined, with the Euro Stoxx 50 and China's Shanghai Composite both closing lower, while US Treasury yields fell, reflecting a flight to safety amid stock market volatility and economic uncertainty.

[object Object]
Preview
9.5
11-05Benzinga
Zoetis Stock Forecast Uncertain Due to Increasing Competitive Challenges

  • Earnings Report: Zoetis Inc. reported third-quarter 2025 adjusted earnings per share of $1.70, surpassing the consensus estimate of $1.62, with adjusted net income increasing by 5% year-over-year to $754 million.

  • Sales Performance: The company generated sales of $2.4 billion, a 1% increase year-over-year, but fell short of the expected $2.41 billion, with declines in monoclonal antibody products and livestock sales.

  • Updated Guidance: Zoetis revised its full-year 2025 sales guidance down to $9.4 billion-$9.475 billion from the previous $9.45 billion-$9.60 billion, reflecting a decrease in expected organic operational growth.

  • Market Reaction: Following the earnings report and guidance update, Zoetis stock fell by 13.14% to $125.39, raising concerns among investors about competition and growth potential in the companion animal segment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zoetis Inc (ZTS) stock price today?

The current price of ZTS is 121.25 USD — it has increased 0.94 % in the last trading day.

arrow icon

What is Zoetis Inc (ZTS)'s business?

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

arrow icon

What is the price predicton of ZTS Stock?

Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 181.71 USD with a low forecast of 152.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zoetis Inc (ZTS)'s revenue for the last quarter?

Zoetis Inc revenue for the last quarter amounts to 2.40B USD, increased 0.50 % YoY.

arrow icon

What is Zoetis Inc (ZTS)'s earnings per share (EPS) for the last quarter?

Zoetis Inc. EPS for the last quarter amounts to 1.63 USD, increased 8.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zoetis Inc (ZTS)'s fundamentals?

The market is revising Downward the revenue expectations for Zoetis Inc. (ZTS) for FY2025, with the revenue forecasts being adjusted by -0.6% over the past three months. During the same period, the stock price has changed by -19.04%.
arrow icon

How many employees does Zoetis Inc (ZTS). have?

Zoetis Inc (ZTS) has 13800 emplpoyees as of November 13 2025.

arrow icon

What is Zoetis Inc (ZTS) market cap?

Today ZTS has the market capitalization of 53.43B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free